As of Aug 26
| +0.24 / +2.93%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 32.00, with a high estimate of 41.00 and a low estimate of 15.00. The median estimate represents a +279.60% increase from the last price of 8.43.
The current consensus among 6 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.